FDA Accepts Outlook Therapeutics' Resubmitted BLA for Wet AMD Drug, Sets July 29 PDUFA Date
OTLK has more than doubled off its 52-week low of $0.161.
Summary
The FDA has accepted Outlook Therapeutics' resubmitted Biologics License Application (BLA) for ONS-5010/LYTENAVA™ for wet AMD, designating it a Class 1 review. This follows the company's successful appeal to the FDA in late May and the BLA resubmission on June 1. The acceptance is a crucial positive step for the company, which has recently faced significant financial challenges and dilution. A final FDA decision is now expected by the PDUFA target action date of July 29, 2026.
At the time of this announcement, OTLK was trading at $1.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $185.8M. The 52-week trading range was $0.16 to $3.39. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.